Deep Brain Stimulation for Tremor Associated with Underlying Ataxia Syndromes: A Case Series and Discussion of Issues by Oyama, Genko et al.
Articles
Deep Brain Stimulation for Tremor Associated with Underlying Ataxia


















, Sankarasubramoney H. Subramony , Tetsuo Ashizawa & Michael S. Okun
1 1 1,2*
1 Department of Neurology, 2 Department of Neurosurgery, University of Florida, Center for Movement Disorders and Neurorestoration, Gainesville, FL, USA
Abstract
Background: Deep brain stimulation (DBS) has been utilized to treat various symptoms in patients suffering from movement disorders such as Parkinson’s disease,
dystonia, and essential tremor. Though ataxia syndromes have not been formally or frequently addressed with DBS, there are patients with ataxia and associated
medication refractory tremor or dystonia who may potentially benefit from therapy.
Methods: A retrospective database review was performed, searching for cases of ataxia where tremor and/or dystonia were addressed by utilizing DBS at the
University of Florida Center for Movement Disorders and Neurorestoration between 2008 and 2011. Five patients were found who had DBS implantation to
address either medication refractory tremor or dystonia. The patient’s underlying diagnoses included spinocerebellar ataxia type 2 (SCA2), fragile X associated
tremor ataxia syndrome (FXTAS), a case of idiopathic ataxia (ataxia not otherwise specified [NOS]), spinocerebellar ataxia type 17 (SCA17), and a senataxin
mutation (SETX).
Results: DBS improved medication refractory tremor in the SCA2 and the ataxia NOS patients. The outcome for the FXTAS patient was poor. DBS improved
dystonia in the SCA17 and SETX patients, although dystonia did not improve in the lower extremities of the SCA17 patient. All patients reported a transient gait
dysfunction postoperatively, and there were no reports of improvement in ataxia-related symptoms.
Discussion: DBS may be an option to treat tremor, inclusive of dystonic tremor in patients with underlying ataxia; however, gait and other symptoms may possibly
be worsened.
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Introduction
Though deep brain stimulation (DBS) has been utilized as a
treatment for a variety of neurological and neuropsychiatric disorders,
ataxia syndromes have been rarely addressed.1–5 There are specific
symptoms other than the ataxia that may possibly be treated through
the use of DBS. Most prominently, these symptoms include medication
refractory tremor and dystonia. We present a series of five such
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patients where tremor, or alternatively dystonia in the setting of an
ataxia syndrome was addressed by utilizing DBS.
To date, there are few available reports of the effects of DBS on
patients with ataxia,1,6–10 Mostly, these cases highlight improvement of
symptoms via stimulation, although side effects were not always detailed.
There are several reports of successful treatment of dystonia with DBS in
pantothenate kinase-associated neurodegeneration (PKAN),7 which is
also a syndrome that may result in ataxia symptoms. The remaining
published studies focused on tremor suppression with thalamic and/or
subthalamic stimulation in spinocerebellar ataxia type 2 (SCA2),1,8
spinocerebellar degeneration (SCD),9 and fragile X tremor ataxia
syndrome (FXTAS).6,10–13 There have not been previous reports of DBS
for spinocerebellar ataxia type 17 (SCA17)-related dystonia or in DBS for
a senataxin mutation-related dystonia. We will discuss the pre- and
postoperative course of thalamic ventralis intermedius nucleus (Vim)
DBS that was employed for tremor cases associated with SCA2, FXTAS,
and an idiopathic, young-onset ataxia where no genetic mutation was
uncovered (ataxia not otherwise specified [NOS]). We will also report the
outcome of dystonia treated with globus pallidus interna (GPi) DBS in a
case of SCA17 and in a single case of a senataxin (SETX) mutation.
Methods
A retrospective Institutional Review Board-approved database
review (UF-INFORM) of all DBS patients operated on at the
Center for Movement Disorders & Neurorestoration at the
University of Florida from 2008 to 2011 was performed. We screened
cases for the presence of an ataxia syndrome, and included only
patients without another primary neurological or neuropsychiatric
diagnosis (Parkinson’s disease, dystonia, essential tremor, Huntington’s
disease, obsessive compulsive disorder, and Tourette’s syndrome).
The potential risks and benefits of DBS were discussed at length
with each patient, prior to surgical intervention. Each patient
underwent risk stratification by the University of Florida Center for
Movement Disorders and Neurorestoration Interdisciplinary DBS
team. This risk stratification involved an evaluation by movement
disorders neurology, neurosurgery, neuropsychology, psychiatry,
physical therapy, occupational therapy, and speech/swallow therapy.
Microelectrode recording was performed without anesthesia in an
attempt to identify and map the corresponding target (Vim or GPi).
Macrostimulation was performed to confirm thresholds for benefits
and side effects and a 3387 DBS lead (Medtronic, Minneapolis, MN)
was implanted. The placement of the ventral electrode tip was
confirmed postoperatively by computed tomography (CT)–magnetic
resonance imaging (MRI) fusion. A second DBS lead was placed
sterotactically, 2 mm anterior to the first lead, on a single case
(FXTAS). One month following lead implantation, subclavicular
generators (Soletra, Medtronic) were implanted under general
anesthesia and connected to the DBS leads. The stimulators were
activated 30 days following the initial surgery, and stimulation-induced
thresholds were checked for side effects and benefits at each contact on
the DBS lead. Empirical programming in the clinic occurred on
average, once a month for 6 months, so that the most effective clinical
settings could be identified for chronic treatment. Pre–post rating scale
scores are summarized in Table 1 and postoperative DBS lead
locations (ventral tip) derived from CT–MRI fusion are summarized in
Table 2. Programming parameters are summarized in Table 3.
Case reports
Case 1: SCA2
A 41-year-old right-handed Caucasian female of Cuban decent
presented with tremor in her hands. She had been asymptomatic until
Table 1. Pre- and Postoperative Validated Rating Scales for the Ataxia DBS Cases
Subject Scale Preop Score 6 Months Post DBS 12 Months Post DBS
SCA2 TRS: motor 51 DBS on: 31 DBS on: 26
DBS off: 35 DBS off: 33
FXTAS TRS: motor 60 DBS on: 57 DBS on: 45
DBS off: 60 DBS off: 62
Ataxia NOS TRS: motor 40 DBS on: 27 N/A
DBS off: 29 N/A
SCA17 BFMDRS 15 DBS off 32 DBS on 17
SETX UDRS 34 DBS on: 34 DBS on: 38
DBS off: 35
Ataxia NOS, Ataxia Not Otherwise Specified; BFMDRS, Burke–Fahn–Marsden Dystonia Rating Scale; DBS, Deep Brain Stimulation; FXTAS, Fragile X Ataxia Syndrome;
SCA2, Spinocerebellar Ataxia Type 2; SCA17, Spinocerebellar Ataxia Type 17; SETX, Senataxin Mutation-associated Ataxia; TRS, Tremor Rating Scale; UDRS, Unified
Dystonia Rating Scale.
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age 27 and, over the course of many years, she developed a gait ataxia,
which required the use of a wheelchair by age 41. Coincident with the
gait decline was a decrement in speech and swallowing function. In the
2 years prior to her presentation, she had developed difficulty with
handwriting, signing her name, and in her activities of daily living
(such as eating) due to her tremor and also her ataxia. On neurological
examination, she had a very mild dysmetria, and a clumsiness in her
upper extremities as well as a moderate truncal and gait ataxia. There
were slow saccadic movements on horizontal gaze, and her deep
tendon reflexes were diminished. Her tremor was limited to her upper
extremities, and was more distal than proximal. The tremor was
present with rest and posture, but most pronounced with action. She
had mild bradykinesia, but no rigidity. She underwent genetic testing,
which revealed 44 CAG repeats on the ATXN gene, which confirmed
the diagnosis of SCA2.
She was treated with maximally tolerated dosages of primidone
250 mg and levetiracetam 3000 mg, which failed to suppress her
tremor. Botulinum toxin injections (total 235 units) in her forearm
decreased tremor, but resulted in intolerable muscular weakness.
Given her poor response to treatment, she elected to have a left Vim
DBS in an attempt to suppress her right-hand tremor and to improve
her activities of daily living, including her eating and her handwriting.
After surgery, she reported improvements from the implantation
effects alone with resolution of her resting tremor, and improvement of
both postural and action tremor of her right arm. However, her gait
worsened following the surgery, and she required inpatient rehabilita-
tion for 2 weeks to restore her gait to her preoperative baseline. At her
12-month follow-up visits, her Fahn–Tolosa–Marı́n Tremor Rating
Scale (TRS) scores had markedly improved compared with baseline.
Her ataxia did not change. She did not elect to undergo a contralateral
Table 2. Postoperative Lead Locations for Ataxia DBS Patients
Subject Target Right Left
SCA2 Vim X 11.2, Y –6.4, Z –1.9
FXTAS Vim X –12.9, Y –9.9, Z –0.79
VOA X –13.4, Y –7.89, Z –1.7
Ataxia NOS Vim X –13, Y –6.91, Z –3.5
SCA17 GPi X 18, Y 1.8, Z –4.1 X –20.5, Y 1.8, Z –6.6
SETX GPi X 19.5, Y 0.71, Z –4.57 X –22, Y –0.3, Z –4.2
Lead locations were derived from computed tomography–magnetic resonance imaging fusion.
Measurements were made in reference to the mid-commissural point: Y, anteroposterior; X, mediolateral; Z, axial; Vim, Thalamic Ventralis Intermedius Nucleus; GPi,
Posteroventral Globus Pallidus Internus; VOA–VOP, Thalamic Ventralis Oralis Anterior and Ventralis Oralis Posterior.
Ataxia NOS, Ataxia Not Otherwise Specified; FXTAS, Fragile X Ataxia Syndrome; SCA2, Spinocerebellar Ataxia Type 2; SCA17, Spinocerebellar Ataxia Type 17; SETX,
Senataxin Mutation-associated Ataxia.













SCA2 Left Vim 2 C 1.8 90 135 12
FXTAS Left VOA 2 C 3.3 120 135 12
Left Vim 6 C 3.3 150 135
Ataxia NOS Left Vim 0 2 3.2 180 135 6
SCA17 Left GPi 1 3 3.2 450 185 12
Right GPi 1 3 3.2 450 185
SETX Left GPi 1 C 4.6 180 100 12
right GPi 1, 2 C 3.6 150 100
Ataxia NOS, Ataxia Not Otherwise Specified; FXTAS, Fragile X Ataxia Syndrome; GPi, Globus Pallidus Interna; SCA2, Spinocerebellar Ataxia Type 2; SCA17,
Spinocerebellar Ataxia Type 17; SETX, Senataxin Mutation-associated Ataxia; Vim, Ventralis Intermedius Nucleus; VOA, Ventralis Oralis Anterior.
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DBS, citing satisfaction with tremor control, and also a fear of risking
gait deterioration.
Case 2: FXTAS
A 72-year-old male presented with tremor that was interfering with
his activities of daily living. At the time of his visit, he required
caregiver assistance to dress, shave, and to eat. His difficulties began 15
years prior, and he initially reported he had a minor intention tremor
of the right hand, which slowly progressed to include his head and later
his body. He eventually developed balance impairment, a wide-based
gait, and he reported generalized clumsiness. His family history was
significant for tremor in his mother, and in his brother, who had
similar symptoms. He had a normal cognitive examination. His
baseline TRS motor score was 60. He had severe tremor of both upper
extremities with posture and intention. His postural tremor and
intention tremors were worse than his resting tremor. The tremor
prohibited him from completing all of the writing portions of the
examination. His cerebellar examination revealed dysmetria and
dysdiadochokinesis. He had a cerebellar rebound phenomenon in both
upper extremities, and past pointing when performing the finger chase
maneuver. He could not perform tandem walking, but was able to
walk unassisted, though it was unsteady. Polyneuropathy was present,
with moderate proprioceptive problems, and he had mild pain and
temperature loss (more in the toes, and ankles but also present in his
fingers). His reflexes were diminished in his arms and legs, and his
ankle jerks were absent. A formal diagnosis of FXTAS was made
through the use of genetic testing, which revealed a pre-mutation in
the FMR1 gene with 100 CGG trinucleotide repeats.
He was treated with primidone 250 mg and propranolol 20 mg and
he had a very mild benefit, which quickly waned. He was successfully
treated with botulinum toxin A to address his head tremor. His severe
arm tremor and his inability to perform his activities of daily living led
to him to considering DBS therapy. After placement of the first lead at
the Vim–VOP border, there was mild tremor suppression in the
resting tremor and postural tremor, but there remained severe
intentional tremor. A second lead was then placed in the same sitting
at the VOP–VOA border and, intraoperatively, there was a near
complete tremor suppression, and only a mild residual ataxia. He
underwent monthly visits for reprogramming, and despite multiple
setting changes he did not make functional improvements in the
tremor without experiencing intolerable side effects of stimulation
including unsteady gait. His family stated his tremor was mildly
improved. Postoperatively at 6 months, his TRS scores remained
similar to his preoperative scores; however, he felt he had some
improvement of his postural and truncal tremors.
Case 3: Ataxia NOS
A 40-year-old male was referred for evaluation of ataxia, dystonia,
and tremor. At the age of 12 years he developed head tremor, along with
bilateral hand tremor. The syndrome gradually progressed to include a
writer’s cramp, bilateral foot inversion, ataxia, and gait instability. His
activities of daily living were progressively compromised, and he noted
that his most significant problem was difficulty when attempting to eat
independently. His neurological examination was significant for poor
proprioception and vibratory sense in his feet bilaterally, as well as
generalized depression of his deep tendon reflexes, with absent ankle
jerks, and the presence of Babinski signs bilaterally. He previously
underwent a genetic work-up for his tremor and ataxia which included
SCA1, 2, 3, 6, 7, 8, 10, and Dentatorubral-pallidoluysian atrophy
(DRPLA), and all testing was normal. He was diagnosed with an
idiopathic tremor–ataxia syndrome (ataxia NOS). He was previously
treated with clonazepam and propranolol with only minor benefits, and
levodopa was not helpful. Given the tremor component of his syndrome,
and the effect on his activities of daily living, he elected to undergo a left
Vim DBS implantation.
Intraoperatively, there was successful suppression of the resting
tremor, postural tremor, and intentional tremor; however, there
remained a significant ataxic component to his movements.
Postoperatively, he described himself as ‘‘much improved’’ despite
only mild improvements in his overall functional status. There were
modest improvements on his postoperative TRS scales at 6 months
after surgery. He stated he had a worsening of his gait with stimulation,
but that he could adjust his settings on an as-needed basis, and that he
was able to utilize higher settings while eating and lower settings while
walking. He had no worsening gait, and he observed no change in the
degree of ataxia in his upper extremities.
Case 4: SCA17
A 37-year-old right-handed Caucasian male without a family history
of movement disorders presented with a slowly progressive gait
disturbance over the course of 20 years. His first symptoms of gait
difficulty began at age 12. At age 15, he developed generalized
dystonia, with a severe inversion of his left foot. This progressed to
include a twisting of his neck and shoulders that was worsened by
action. He also developed a postural-action tremor in both of his arms.
His symptoms gradually worsened, and by the time of his presentation
at our clinic, he suffered from marked dystonic posturing of his face,
shoulders, neck, and legs all contributing to gait difficulty. He also had
a moderate, proximal more than distal postural and intention tremor.
This tremor presented bilaterally, and was dystonic in character. His
general neurological examination was otherwise unremarkable, and he
had no clinical signs of gait ataxia.
He was initially diagnosed with a generalized dystonia and trials of
maximally tolerated dosages of levodopa, trihexyphenidyl, baclofen,
and botulinum toxin injections failed to improve his symptoms. Given
his poor response to medication, and marked dystonia, he underwent
staged bilateral GPi DBS surgery to improve the foot dystonia. One
month after his initial DBS programming, he noted dramatic
improvements in his upper extremity dystonic tremor; however, there
was no improvement noted in his lower extremity dystonia. He
reported that his fall frequency of five or six times a day was
unchanged by DBS implantation. Multiple DBS programming
adjustments did not improve his gait. The ‘‘Off’’ DBS condition
revealed a re-emergence of upper extremity dystonic tremor. Three
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months postoperatively he developed an ataxic wide-based quality to
his gait, and his fall frequency increased. This was present whether on
or off DBS. He also observed new slurring of his speech, and his
neurological examination revealed mild dysarthria, bilateral dysmetria,
and severe gait ataxia without saccadic or ocular pursuit abnormalities.
There was significant gait and stance ataxia, and mild appendicular
ataxia. He was able to stand only with assistance, and he began using a
power scooter. His dystonia scales continued to worsen at his 12-
month follow-up and multiple DBS settings were attempted without
dystonia and ataxia benefit. He was, however, able to maintain tremor
benefit. He had negative genetic testing results for DYT1, and for
SCAs 1, 2, 3, 6, 7, 8, 10, and Dentatorubral-pallidoluysian atrophy
(DRPLA). His molecular genetic testing for SCA17, however,
demonstrated an expanded allele of 43 repeats, and a normal allele
of 32 CAA/CAG repeats in the TATA-binding protein gene.
Case 5: senataxin mutation
A 19-year-old right-handed male was referred for ataxia and
myoclonic jerking of his extremities. His symptoms began in infancy
with hypotonia and multiple delayed motor milestones. He began
talking at an appropriate age, but his speech was described as slurred
from a very early age. At age 2, his mother reported that his arms and
his head were held in an abnormal posture, and that he had titubation
of his body when walking. During his school years, he required
personal aides in the classroom setting because of his tremor and
jerking, both of which interfered with his normal activities. His tremor
had become disabling over the past 5 years, and he utilized a straw to
drink because of his inability to hold a cup. His neurological
examination revealed limited horizontal gaze in both directions,
though his oculocephalics were normal. His horizontal saccades were
slow, but without nystagmus. He had a cerebellar rebound
phenomenon bilaterally, and he had prominent dysmetria on finger-
to-nose, and heel-to-shin testing. His gait was wide based with dystonic
inward posturing of his feet, which was worse on his left side. His
hands were dystonic bilaterally. There was a bilateral upper extremity
tremor, and it was both resting and postural, and the tremor had an
irregular frequency. Fast myoclonic jerks were observed in both upper
extremities at rest, and with action, more in the left than right upper
extremity. His family reported that his neurological condition was
slowly worsening and was definitely progressive over many years. His
previous work-up included a gene test for SCA1, 2, 3, 6, 7, 8, and 10,
all of which were within normal range. Brain MRI, electroencephalo-
gram, and an electrocardiogram were all normal. Wilson’s disease and
Niemann–Pick disease work-ups were negative and a skin biopsy for
electron microscopy was negative. However, an amino acid change
was found on codon 992 (lysine to arginine) on the SETX gene, and he
was diagnosed with a senataxin-associated myoclonus, dystonia, and
tremor syndrome. He declined testing for the myoclonus dystonia gene
because of financial constraints.
Multiple medications were titrated to maximally tolerated dosages in
an attempt to treat his dystonia, tremor, and myoclonus, and these
included primidone, valproic acid, clonazepam, acetazolamide,
levodopa, buspirone, and levetiracetam. The propranolol 30 mg and
gabapentin 1200 mg could mildly suppress his tremor, and he
remained on these medications at the time of presentation. He elected
to undergo staged bilateral GPi DBS surgery with the goal of
improving the dystonic posturing and tremor in his hands, and to
attempt to improve eating and handwriting.
Postoperatively, he had improvement in his dystonic tremor and an
almost complete resolution of his myoclonus, although overall his
Unified Dystonia Rating Scale (UDRS) was not improved. After his
second GPi DBS was placed, he reported some transient worsening of
his gait, which he said slowly returned to baseline preoperative levels.
He was satisfied with his functional improvement, despite the lack of
objective improvements on his UDRS. His handwriting was better,
and he could hold a pen and he could type as a result of the DBS. He
was able to eat and drink without spilling, which was a personal
preoperative goal. He rated himself as much improved.
Discussion
In each of the five ataxia patients receiving DBS therapy, all
reported postoperative improvements in tremor. However, dystonia
did not improve in two patients. The cases were all associated with
some level of postoperative gait impairment.
Rhythmic postural and action tremor in ataxia patients seemed to
respond to Vim DBS in a similar way to what has been observed in
essential tremor; however, the ataxia, clumsiness, and gait dysfunction did
not respond. In our cohort, the SCA2 patient had the greatest amount of
tremor suppression, and she reported ipsilateral as well as contralateral
benefit. The Ataxia NOS patient also had excellent tremor suppression. In
contrast, the FXTAS patient had a dramatic intraoperative improvement
in his tremor, but the improvement was not sustained, even with the
addition of a second DBS lead into the VOA/VOP region. Interestingly in
the SCA2 and ataxia NOS patients, the TRS markedly improved in the
off-DBS setting when compared with baseline, but minimally improved in
the on-DBS condition, which contrasted to the FXTAS patient where
improvement in the TRS score was only seen after turning the DBS on.
This contrast in outcomes could possibly have been due to differences in
the degree of the microlesion (i.e. implantation) effect. The single case
reports in the literature on DBS in ataxia patients highlight the potential,
and also the shortcomings to applying this therapeutic approach to a
complex and heterogenous population.1,6,8–13 Whether the ataxia can
worsen due to DBS remains controversial, and though gait worsened it is
important to recognize that gait and balance may also worsen following
Vim DBS for essential tremor.14 A staged Vim DBS procedure has been
reported to worsen ataxia following a second lead implantation in a
FXTAS case.11 Therefore, collectively one might conclude that caution
should be exercised, and that a preoperative risk–benefit ratio discussed
prior to considering bilateral procedures in patients with ataxia.
Dystonic tremor responded to GPi DBS in SCA17 and in the
senataxin mutation cases and this contrasted to the response seen in
dystonia. GPi DBS has been reported to improve dystonic tremor as
well as dystonia;15 however, the results for dystonia in the setting of
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ataxia were not as robust as has been reported in primary generalized
and in cervical dystonia.
Although our case series included heterogeneous cases and a small
number of cases, the results demonstrated the potential benefits and
also the side effects of DBS surgery in patients with ataxia syndromes.
Additionally, the discrepancy between subjective and objective
improvement in our cases may possibly indicate the shortcomings of
traditional objective rating scales that may not capture mild
improvements. Quality of life and other measures should be included
in future ataxia DBS studies. It is likely that a subset of carefully
selected patients may benefit from DBS, though the outcomes will
likely be less robust than in essential tremor and in primary dystonia.
The unilateral procedures in our small case series resulted in side
effects and this issue should be kept in mind by treating clinicians who
may opt for a staged approach with interval and careful clinical
evaluation before proceeding to implant a contralateral DBS lead.
Each ataxia DBS candidate should be counseled preoperatively about
potential gait issues, and also should be counseled that DBS will be
unlikely to benefit the ataxic components of their disease.
In conclusion, DBS may be an option to treat tremor, including
dystonic tremor in patients with underlying ataxia; however, gait and
other symptoms may be worsened. Whether choosing unilateral,
staged bilateral, or simultaneous bilateral DBS implantation(s) for
ataxia syndromes, a careful preoperative risk benefit discussion should
be pursued with patients and families.
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